Provider Perspectives on Use of Medical Marijuana in Children With Cancer

Ananth, Prasanna; Ma, Clement; Al‐Sayegh, Hasan; Kroon, Leah; Klein, Victoria; Wharton, Claire; Hallez, Elise; Braun, Ilana M.; Michelson, Kelly; Rosenberg, Abby R.; London, Wendy B.; Wolfe, Joanne

doi:10.1542/peds.2017-0559

Cited by 61 publications

(66 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Limited information is available on the therapeutic use of Cannabis in pediatric patients. Cannabis is usually considered when the clinical condition becomes intractable to other types of treatments [5]. This is seen, for example, in treatment of children with refractory epileptic encephalopathy, in particular Lennox-Gastaut syndrome and Dravet syndrome [6].…”

Section: Therapeutic Applicationsmentioning

confidence: 99%

Pediatric Dosing Considerations for Medical Cannabis

Alcorn¹,

Vuong²,

Wu³

et al. 2019

Recent Advances in Cannabinoid Research

View full text Add to dashboard Cite

For patients who fail conventional therapies, ability to access medical Cannabis may offer a therapeutic alternative that addresses their unmet clinical need. However, a paucity of clinical trial evidence has led to ambiguous pediatric dosing guidelines for medical Cannabis, a situation further complicated by the impact of developmental maturation of the pharmacokinetic (PK) and pharmacodynamic (PD) processes governing drug effect and dosing requirements. The pediatric population is very heterogeneous, and dissimilar developmental trajectories result in important differences in the rate and extent of cannabinoid absorption, distribution, elimination, and response both between and within pediatric age group classifications. These developmental changes will require the prescribing caregiver to consider age-specific dosage regimens that may demand continual modification as the child ages. The chapter that follows emphasizes the impact of agerelated changes in PK and PD processes as important considerations in pediatric dosing recommendations for medical Cannabis.

show abstract

Section: Therapeutic Applicationsmentioning

confidence: 99%

Pediatric Dosing Considerations for Medical Cannabis

Alcorn¹,

Vuong²,

Wu³

et al. 2019

Recent Advances in Cannabinoid Research

View full text Add to dashboard Cite

show abstract

“…Los estudios disponibles presentan períodos de seguimiento máximos de un año. Se requieren estudios de farmacovigilancia activa para caracterizar los problemas de seguridad entre los nuevos usuarios de derivados de cannabis medicinales incluyendo niños y adolescentes (32,34) .…”

Section: Efectos Adversosunclassified

“…Las precauciones para su uso son las enfermedades cardiovasculares severas (arritmias, hipertensión no controlada, falla cardíaca severa), esquizofrenia y otras enfermedades psicóticas, el embarazo y la lactancia (10,34).…”

Section: Efectos Adversosunclassified

Derivados cannábicos para uso medicinal en niños y adolescentes: aportes para un uso responsable y seguro

Notejane

Zunino

Rodríguez

et al. 2018

ADP

View full text Add to dashboard Cite

show abstract

“…His concerns about cannabis use in clinical practice are reflective of the apprehension observed among some health care workers. 3 Although we too have concerns regarding cannabis use among patients with cancer, it is important to note that the risks of cannabis are not as well codified as, for example, those for tobacco. Connecting cannabis to negative outcomes is challenging, because use cannot easily be uncoupled from socioeconomic factors, legal issues, or other substances such as tobacco, alcohol, and other drugs.…”

Section: Reply To the Pot Dealer State Harms Patients With Cancermentioning

confidence: 99%